News & Updates

Treatment with deucravacitinib achieves better efficacy than placebo and apremilast in patients with moderate-to-severe plaque psoriasis, while also yielding a good safety profile, reports a recent study.

Among adults and adolescents with atopic dermatitis (AD), ruxolitinib cream helps sustainably improve itching, reports a recent analysis.

In the treatment of children with atopic eczema, ciclosporin is linked to a more rapid response while methotrexate (MTX) is associated with sustained disease control following discontinuation, a study has found.

Applying roflumilast cream topically once-a-day helps clear plaque psoriasis in 8 weeks, according to pooled data from the phase III DERMIS-1 and DERMIS-2 trials.

Rocatinlimab improved disease severity in patients with moderate-to-severe head and neck atopic dermatitis (H&N AD), a post hoc analysis of a phase IIb trial has shown.

In the interim analysis of the ongoing phase III ALLEGRO-LT trial, the investigational oral JAK3*/TEC inhibitor ritlecitinib demonstrated long-term safety and remarkable scalp hair regrowth in adults and adolescents with alopecia areata (AA).

Treatment with bimekizumab for up to 2 years appears to be tolerated well in patients with moderate-to-severe plaque psoriasis, with no increased risk of adverse events (AEs) aside from a higher frequency of mild-to-moderate oral candidiasis, according to pooled analyses of data from eight randomized controlled trials (RCTs).

The adalimumab biosimilar BI 695501 has demonstrated equivalent pharmacokinetics to the reference product, with highly comparable efficacy, immunogenicity, and safety in patients with chronic plaque psoriasis, according to data from the phase III VOLTAIRE-X trial.